THE UROLUME STENT: A REASONABLE TREATMENT FOR THE POST-PROSTATE CANCER TREATMENT BLADDER OUTLET OBSTRUCTION

Hypothesis / aims of study
The UroLume® Urethral Stent has recently been removed from the market. We have been using this device in the treatment of the difficult to treat, post-prostatectomy urethral stricture since 2001. Herein we describe our experience with this treatment modality showing that it provided a viable option for the devastated, obstructed outlet following prostate cancer treatment.

Study design, materials and methods
We conducted an IRB approved retrospective study of all men at our facility who underwent placement of the Urolume stent from January 2001- January 2012. Records were reviewed for patient demographics, outcomes and complications. We specifically evaluated urinary continence, ingrowth of the Urolume stent, need for repeat operations and complications related to this treatment including AUS erosion.

Results
Forty-five men underwent placement of the Urolume stent with an average follow up of 55.8 months. Of these 45, 41 had either simultaneous or subsequent placement of an AUS with an overall continence rate of 35/45 (78%). Ingrowth was seen in 16/45 (36%) and AUS erosion was seen in 8/41 (19.5%). Of the 16 patients treated for ingrowth, the average number of treatments was 2.7 per patient. There was no association between treatment for ingrowth and rate of AUS erosion (p=0.92).

Interpretation of results
While no longer commercially available, our long term data indicates that the Urolume was a reasonable minimally invasive procedure treatment option for the devastated, obstructed outlet providing a reasonable rate of need for subsequent interventions. When combined with the AUS it also provides a high rate of urinary continence. The alternative open operative reconstructive options have similar limitations with possibly greater morbidity.

Concluding message
While no longer commercially available, our long term data indicates that the Urolume stent combined with the AUS may be a reasonable option for the devastated, obstructed outlet. It provided a high rate of urinary continence and a reasonable rate of subsequent interventions with a minimally invasive procedure. The rate of retreatment and AUS erosion was higher in this specific population; however, with this difficult reconstructive problem, the alternative treatment options have similar limitations with possibly greater morbidity.

References

Disclosures
Funding: None Clinical Trial: No Subjects: HUMAN Ethics Committee: Duke University IRB Helsinki: Yes Informed Consent: No